Cas:205180-51-4 1,5-dibromopentan-2-yl acetate manufacturer & supplier

Chemical Name:1,5-dibromopentan-2-yl acetate

CAS.NO:205180-51-4

Synonyms:2-ACETOXY-1,5-DIBROMOPENTANE—CLEAR LIQUID,D20 1.58;2-Acetoxy-1,5-dibromopentane

Molecular Formula:C₇H₁₂Br₂O₂

Molecular Weight:287.97700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:302.2ºC at 760 mmHg

Density:1.652g/cm3

Index of Refraction:1.504

PSA:26.30000

Exact Mass:285.92000

LogP:2.48810

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-ACETOXY-1,5-DIBROMOPENTANE—CLEAR LIQUID,D20 1.58 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Acetoxy-1,5-dibromopentane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-ACETOXY-1,5-DIBROMOPENTANE—CLEAR LIQUID,D20 1.58 Use and application,2-ACETOXY-1,5-DIBROMOPENTANE—CLEAR LIQUID,D20 1.58 technical grade,usp/ep/jp grade.

Related News: The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 1,5-dibromopentan-2-yl acetate manufacturer Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 1,5-dibromopentan-2-yl acetate supplier Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 1,5-dibromopentan-2-yl acetate vendor The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 1,5-dibromopentan-2-yl acetate factory In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.”